Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Sales | 152,365 | 117,279 | 102,003 | 115,830 | 136,455 |
| Cost of Goods | 33,943 | 15,922 | 21,587 | 18,589 | 23,018 |
| Gross Profit | 118,422 | 101,357 | 80,416 | 97,241 | 113,437 |
| Operating Expenses | 85,305 | 26,609 | 24,469 | 22,244 | 20,408 |
| Operating Income | 34,060 | 75,670 | 56,534 | 75,586 | 93,047 |
| Interest Expense | 3,104 | 1,759 | 2,055 | 1,754 | 1,752 |
| Other Income | -945 | 498 | 331 | 274 | 221 |
| Pre-tax Income | 30,011 | 74,409 | 54,810 | 74,106 | 91,516 |
| Income Tax | 7,326 | 14,301 | -11,960 | -142,481 | 58 |
| Net Income Continuous | 22,685 | 60,108 | 66,770 | 216,587 | 91,458 |
| Net Income | $22,685 | $60,108 | $66,770 | $216,587 | $91,458 |
| EPS Basic Total Ops | 0.16 | 0.44 | 0.49 | 1.53 | 0.64 |
| EPS Basic Continuous Ops | 0.16 | 0.44 | 0.49 | 1.53 | 0.64 |
| EPS Diluted Total Ops | 0.16 | 0.43 | 0.45 | 1.48 | 0.62 |
| EPS Diluted Continuous Ops | 0.16 | 0.43 | 0.46 | 1.48 | 0.62 |
| EBITDA(a) | $47,976 | $77,960 | $59,014 | $77,878 | $95,341 |